Immunomedics Inc., of Boston, reported objective durable responses were achieved with sacituzumab govitecan, its lead antibody-drug conjugate, in a number of patients with advanced, metastatic solid cancers, after failing multiple prior therapies, some including checkpoint inhibitors. The drug previously received breakthrough therapy designation in triple-negative breast cancer patients who have failed prior therapies for metastatic disease.